Prosecution Insights
Last updated: April 19, 2026

Examiner: DUFFY, PATRICIA ANN

Tech Center 1600 • Art Units: 1644 1645

This examiner grants 52% of resolved cases

Performance Statistics

52.3%
Allow Rate
-7.7% vs TC avg
586
Total Applications
+34.7%
Interview Lift
1387
Avg Prosecution Days
Based on 564 resolved cases, 2023–2026

Rejection Statute Breakdown

6.0%
§101 Eligibility
18.6%
§102 Novelty
23.1%
§103 Obviousness
36.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18051468 TREATMENT OF OSTEOGENESIS IMPERFECTA Non-Final OA Genzyme Corporation
17350898 IL-10-CONTAINING VACCINES AND USES THEREOF Non-Final OA The Regents of the University of California
18833541 BIFIDOBACTERIUM BREVE FOR IMPROVING AGING-RELATED COGNITIVE DISORDER AND USE THEREOF Final Rejection WECARE PROBIOTICS CO., LTD.
18879356 NOVEL BIFIDOBACTERIUM BREVE JKL2022 STRAIN AND METHOD FOR PRODUCING CONJUGATED LINOLEIC ACID USING THEREOF Non-Final OA CHUNG ANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
18097461 BACILLUS SP. PRODUCING BIOFLOCCULANT AND BIOSURFACTANT AND USE THEREOF Non-Final OA ZHEJIANG UNIVERSITY
18685422 DEVELOPMENT OF SYNTHETIC PSEUDAMINIC ACID-BASED ANTIBACTERIAL VACCINES AGAINST ACINETOBACTER BAUMANNII Non-Final OA City University of Hong Kong
18178819 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF Non-Final OA University of Florida Research Foundation, Incorporated
18548987 LATERAL FLOW ASSAY FOR DETECTING PATHOGENS IN MILK FROM MASTITIC COWS Non-Final OA Zoetis Services LLC
18504114 MITIGATION OF PATHOGENS IN PORCINE SPECIES Non-Final OA Purina Animal Nutrition LLC
18627462 PHARMACEUTICAL COMPOSITION FOR ALLEVIATIONN, TREATMENT, AND PREVENTION OF SARCOPENIA CONTAINING MICROORGANISM TRANSFORMED WITH CELL SURFACE DISPLAY VECTOR OPERABLY LINKED WITH GENE ENCODING MYOSTATIN AND ACTIVIN A PROTEINS AS ACTIVE INGREDIENT Non-Final OA MOALIFEPLUS CO., LTD.
18627441 Lacticaseibacillus Rhamnosus DY801 and Application Thereof Non-Final OA NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY
17628667 QUANTIFICATION OF BIOCONJUGATE GLYCOSYLATION Non-Final OA GLAXOSMITHKLINE BIOLOGICALS SA
18293007 A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES Non-Final OA Intervet Inc.
18578507 PROBIOTIC COMPOSITION FOR THE TREATMENT OF INCREASED INTESTINAL PERMEABILITY Non-Final OA AB-BIOTICS, S.A.
18552954 NOVEL MICROBE WITH PLASTIC DECOMPOSITION ACTIVITY AND USE THEREOF Non-Final OA INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
18551954 NOVEL RECOMBINANT STRAIN OF MYCOBACTERIUM SMEGMATIS AND USE OF SAME Non-Final OA CLIPSBNC CO., LTD.
17791859 TGFB INHIBITORS AND USE THEREOF Non-Final OA Scholar Rock, Inc.
17911524 COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATIONS THEREOF Non-Final OA AbelZeta Inc.
17999459 Low Diacetyl Yeast Non-Final OA Carlsberg A/S
18055177 RECOMBINANT GAS VESICLE NANOPARTICLES Non-Final OA PUKYONG NATIONAL UNIVERSITY INDUSTRY UNIVERSITY COOPERATION FOUNDATION
17923168 METHODS AND COMPOSITIONS FOR TREATING FRAILTY Non-Final OA Timo E. Strandberg

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month